Wohlmuth-Wieser et al. (2021) reported a case that described the successful treatment of a 34-year-old patient with HS using certolizumab pegol (CZP), an anti-TNF-α medication that lacks the fragment crystallizable (Fc) region preventing active placental transfer. This evidence concerns the gene TNF and histiocytic sarcoma.